Pomotrelvir
Small moleculeexperimentalCOVID-19
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2021 (NCT05011812)
Timeline
Indications
Studied for
Mechanism of action
- Replicase polyprotein 1abINHIBITOR
Replicase polyprotein 1ab inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#C[C@H](C[C@@H]1CCCNC1=O)NC(=O)[C@H](CC1CC1)NC(=O)c1cc2cccc(Cl)c2[nH]1- Mol. weight
- 455.95 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314568 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05543707 | Phase 2 | Sep 21, 2022 | Pardes Biosciences, Inc. |
| NCT05011812 | Phase 1 | Aug 14, 2021 | New Zealand Clinical Research, Pardes Biosciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pardes Biosciences, Inc. | For profit | 2 | 2 | 2 | 2021 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1